Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - CYPRESS BIOSCIENCE INC | a56678exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 12, 2010
CYPRESS BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 0-12943 | 22-2389839 | ||
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) |
| 4350 Executive Drive, Suite 325, San Diego, CA | 92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-2323
Not Applicable
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
Cypress
Bioscience, Inc. (the “Company”) has furnished herewith as Exhibit 99.1 a Company
Update to provide its stockholders with certain information regarding the Company’s recently
announced transaction with BioLineRx Ltd. and other matters relating to its business and strategy.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Company Update dated July 12, 2010. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cypress Bioscience, Inc. |
||||
| Date: July 12, 2010 | /s/ Sabrina Martucci Johnson | |||
| Sabrina Martucci Johnson | ||||
| Executive Vice President, Chief Operating Officer and Chief Financial Officer | ||||
INDEX TO EXHIBITS
| Exhibit | ||
| Number | Description | |
99.1
|
Company Update dated July 12, 2010. |